GLP-1 drugs expanding beyond diabetes into neurology, dermatology, addiction, and autoimmune disease | Research

The takeaway

A comprehensive 2025 review finds GLP-1 receptor agonists deliver HbA1c reductions of 1.5-2.0%, weight loss of 7-24%, and 14-20% MACE reduction, with emerging evidence across neurological, dermatological, respiratory, and addiction applications.

7-24% weight loss + multi-organ benefits
GLP-1 drugs show pleiotropic effects across diabetes, cardiovascular, neurological, and immune systems through shared cellular mechanisms

What the researchers found

GLP-1 RAs achieve HbA1c reductions of 1.5-2.0%, weight loss of 7-24%, and 14-20% MACE reduction. Pleiotropic mechanisms include mitochondrial function enhancement, anti-inflammatory effects, and cellular quality control improvement. Emerging applications span neurology, dermatology, respiratory, addiction, and autoimmune fields.

Why it matters

GLP-1 drugs are arguably the most important new drug class in decades. This review captures the full scope of their therapeutic potential, helping clinicians understand applications far beyond the original diabetes indication.

The numbers in context

HbA1c reduction: 1.5-2.0%. Weight loss: 7-24%. MACE reduction: 14-20%. Reviews enhanced mitochondrial function, anti-inflammatory actions, cellular quality control.

How the study worked

Systematic literature search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through May 2025.

Who was studied

Broad patient populations across multiple disease areas

What this study cannot tell us

Broad review may lack depth on specific emerging applications. Many emerging indications are based on preclinical or early-phase data. Systematic but not a formal meta-analysis.

How to read the evidence

Systematic review of literature through May 2025. Strong evidence base for established applications; emerging applications range from preliminary to moderate evidence.

When this study was published

Published 2025; most current comprehensive review available.

The bigger picture

GLP-1 receptor agonists are redefining pharmacotherapy by addressing multiple diseases simultaneously through shared metabolic and inflammatory pathways. This multi-system approach challenges the traditional one-drug-one-disease model.

Questions still open

Which emerging GLP-1 applications will be validated by phase 3 trials first?
Are the pleiotropic benefits specific to certain GLP-1 agonists or class-wide?
How will cost and access affect the real-world impact of these expanding indications?

Common questions

What conditions can GLP-1 drugs treat besides diabetes?

Beyond diabetes, GLP-1 drugs are established for obesity and cardiovascular protection. Emerging evidence suggests potential benefits for neurological disorders (Parkinson's, Alzheimer's), skin conditions, respiratory diseases, addiction (alcohol, substance use), and autoimmune disorders, though many of these applications are still being studied.

How effective are GLP-1 drugs for weight loss?

GLP-1 receptor agonists produce 7-24% body weight loss depending on the specific drug and dose, making them the most effective weight loss medications currently available. They also reduce cardiovascular events by 14-20% and lower HbA1c by 1.5-2.0%.

Read the original research

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).

Pharmaceutics, 17(8)

View on PubMed ↗Publisher’s paper ↗

Citation

Patel, Shikha; Niazi, Sarfaraz K. (2025). Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).. Pharmaceutics, 17(8). https://doi.org/10.3390/pharmaceutics17081036